SPDR S&P Biotech ETF
0
Funds holding %
of 7,431 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
17.17% more ownership
Funds ownership: 180.79% [Q1] → 197.97% (+17.17%) [Q2]
5% more capital invested
Capital invested by funds: $9.25B [Q1] → $9.7B (+$458M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 15 [Q1] → 15 (+0) [Q2]
10% less funds holding
Funds holding: 672 [Q1] → 608 (-64) [Q2]
41% less repeat investments, than reductions
Existing positions increased: 158 | Existing positions reduced: 267
42% less call options, than puts
Call options by funds: $1.14B | Put options by funds: $1.97B
49% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 103
Research analyst outlook
We haven’t received any recent analyst ratings for XBI.
Financial journalist opinion
Based on 4 articles about XBI published over the past 30 days
Neutral
CNBC Television
3 days ago
Healthcare industry can handle and absorb tariffs, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Power Lunch' to discuss what tariffs mean for the pharma industry, what could be a blockbuster for Eli Lilly and much more.
Neutral
Zacks Investment Research
2 weeks ago
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on January 31, 2006.
Neutral
Seeking Alpha
3 weeks ago
XBI: Surprise Exit Of A Tough Regulator At The FDA
XBI has rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a tougher regulatory environment. Vinay Prasad was only appointed in May, but is now leaving the FDA, meaning there will again be a new Director of the Center for Biologics Evaluation and Research. Prasad's appointment caused XBI to drop in May, but the sector still continued on with its recovery.
Positive
CNBC Television
4 weeks ago
Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector
Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.
Neutral
Investors Business Daily
1 month ago
Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn
Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month, making good on months of threats.
Neutral
Zacks Investment Research
1 month ago
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Neutral
The Street
1 month ago
Trump threatens 50% tariffs on copper, 200% on pharmaceuticals
However, the President did not disclose when the tariffs would take effect.
Negative
Investors Business Daily
1 month ago
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon."
Positive
CNBC Television
1 month ago
It is time for a move higher in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
Neutral
Seeking Alpha
1 month ago
Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI
IBB and XBI are similar in many ways, but their relative past performance does not tell the story. IBB is more concentrated, and that is ultimately why I prefer it to XBI. Both ETFs target a similar objective, and are over-diversified. For reasons I explain here.
Charts implemented using Lightweight Charts™